Background
Methods
Patient characteristics and study design
PD-L1 expression in tumor tissues
PD-1 positive lymphocyte measurements
Statistical analysis
Results
Patient characteristics
PEM ± Platinum ± Bev ( n = 301) | PTX + CBDCA + Bev ( n = 80) | P value | |
---|---|---|---|
Age | 66 [39–92] | 64 [36–79] | 0.025 * |
Sex male/female | 172/129 | 54/26 | 0.094 |
BMI | 21.9 [14.6–33.0] | 22.4 [15.2–30.2] | 0.137 |
Smoking history | |||
Never/past/current | 106/122/73 | 25/33/22 | 0.754 |
Brinkman’s index | 400 [0–920] | 400 [0–3600] | 0.921 |
ECOG PS 0/1/2 | 106/159/36 | 40/36/4 | 0.026 * |
Pathological diagnosis | |||
Adenocarcinoma/others | 287/14 | 75/5 | 0.559 |
Stage (8th edition) | |||
IIIB/IIIC/IVA/IVB/Rec/unknown | 19/4/110/89/77/2 | 11/2/26/18/23/0 | 0.208 |
Driver mutation | |||
EGFR ± /unknown | 87/200/14 | 27/49/4 | 0.679 |
ALK ± /unknown | 15/227/59 | 3/56/21 | 0.410 |
Therapy line | |||
1st line/2nd line/others | 179/83/39 | 60/14/6 | 0.038 * |
Monitoring of leukocyte fractionation during administration of PEM
Characteristics | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
P value | Hazard ratio (95%CI) | P value | Hazard ratio (95%CI) | |
Age | 0.006* | 1.067 (1.018–1.118) | 0.027* | 1.068 (1.007–1.132) |
Sex | 0.588 | 0.797 (0.351–1.810) | 0.125 | 0.413 (0.133–1.279) |
ECOG PS | 0.228 | 3.485 (0.457–26.580) | 0.459 | 0.441 (0.051–3.851) |
Smoking history | 0.425 | 0.691 (0.279–1.713) | 0.261 | 0.492 (0.143–1.694) |
Stage (8th edition) | 0.013* | 0.656 (0.470–0.914) | 0.030* | 0.666 (0.461–0.962) |
Therapy line | 0.630 | 1.232 (0.526–2.887) | 0.876 | 0.918 (0.313–2.690) |
Platinum combination | 0.463 | 1.378 (0.585–3.247) | 0.764 | 0.841 (0.272–2.604) |
Neutrophils (/mm2) | 0.228 | 1.000 (1.000–1.000) | 0.041* | 1.000 (0.999–1.000) |
Lymphocytes (/mm2) | 0.020* | 1.000 (1.000–1.001) | 0.033* | 1.001 (1.000–1.001) |
Monocytes (/mm2) | 0.337 | 1.001 (0.999–1.003) | 0.016* | 1.001 (1.001–1.007) |
NLR | 0.023* | 0.693 (0.505–0.951) | ※ | ※ |
Association of leukocyte fractionation with clinical outcomes in PEM-based regimens
Association of NLR with clinical outcomes in PEM-based regimens
PD-L1 expression levels in tumor tissues in the long-term PEM administration group
Measurement of PD-1 lymphocytes in the long-term PEM administration group
Effect of preceding PEM on ICI treatment
Efficacy | Long-term administration ( n = 11) | Intermediate-term administration ( n = 16) | Short-term administration ( n = 55) |
---|---|---|---|
Cycles | 6.1 ± 8.5 | 5.6 ± 3.2 | 6.2 ± 8.3 |
PFS (month) | 5.5 ± 6.9 | 3.8 ± 2.7 | 3.4 ± 4.4 |
Adverse effects | Long-term administration ( n = 11) | Intermediate-term administration ( n = 16) | Short-term administration ( n = 55) |
---|---|---|---|
irAE | 5 (45.5%) * | 3 (18.8%) | 10 (18.2%) |
ILD | 4 (36.3%) | 2 (12.5%) | 2 (3.6%) |
Others | 1 (9.1%) | 1 (6.3%) | 9 (16.4%) |